EJSO小类一区

您当前的位置: 首页 > SCI投稿 > EJSO小类一区

Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study.

Abstract:

INTRODUCTION:For stage III colon cancer (CC), surgery followed by chemotherapy is the main curative approach, although optimum times between diagnosis and surgery, and surgery and chemotherapy, have not been established. MATERIALS AND METHODS:We analysed a population-based sample of 1912 stage III CC cases diagnosed in eight European countries in 2009-2013 aiming to estimate: (i) odds of receiving postoperative chemotherapy, overall and within eight weeks of surgery; (ii) risks of death/relapse, according to treatment, Charlson Comorbidity Index, time from diagnosis to surgery for emergency and elective cases, and time from surgery to chemotherapy; and (iii) time-trends in chemotherapy use. RESULTS:Overall, 97% of cases received surgery and 65% postoperative chemotherapy, with 71% of these receiving chemotherapy within eight weeks of surgery. Risks of death and relapse were higher for cases starting chemotherapy with delay, but better than for cases not given chemotherapy. Fewer patients with high comorbidities received chemotherapy than those with low (P < 0.001). Chemotherapy timing did not vary (P = 0.250) between high and low comorbidity cases. Electively-operated cases with low comorbidities received surgery more promptly than high comorbidity cases. Risks of death and relapse were lower for elective cases given surgery after four weeks than cases given surgery within a week. High comorbidities were always independently associated with poorer outcomes. Chemotherapy use increased over time. CONCLUSIONS:Our data indicate that promptly-administered postoperative chemotherapy maximizes its benefit, and that careful assessment of comorbidities is important before treatment. The survival benefit associated with slightly delayed elective surgery deserves further investigation.

展开更多

EJSO

EJSO-EUR J SURG ONC

最新影响因子：4.037	期刊ISSN：0748-7983	CiteScore：
出版周期：Monthly	是否OA：YES	出版年份：1985

期刊官方网址：http://www.ejso.com/

期刊投稿地址：http://ees.elsevier.com/ejso/default.asp?acw=3

自引率：5.50%	研究方向：医学-外科
出版地区：ENGLAND

SCI期刊coverage：Science Citation Index Expanded（科学引文索引扩展）

NCBI查询：PubMed Central (PMC)链接全文检索(pubmed central)

专业编辑在线一对一答疑及时解决您的问题

EJSO 期刊简介

英文简介：

Surgical Oncology has finally come of age and EJSO continues to play a major role in dissemination of information and knowledge relating to this surgical specialty. Published eight times a year, it presents original articles and state-of-the-art reviews of immediate interest to surgical oncologists. In addition, papers are published on chemotherapy, radiotherapy, epidemiology and pathology of cancer. The articles published also reflect the importance of communication between the laboratory and the clinician. Features Include: Clinical Trials Section Clinical Debate Section Early 'fast-track' publication Regular Reviews Education Section Research Areas Include: Epidemiology and preventive aspects of oncology Diagnosis, including imaging All aspects of therapy, including radiotherapy and chemotherapy Application of new equipment to surgical and clinical oncology Methods of assessing results of treatment Case reports that advance clinical and pathological knowledge Computing in relation to oncology EJSO is abstracted/indexed by: Index Medicus; EMBASE; ASCA; Science Citation Index.

中文简介：（来自Google、百度翻译）

外科肿瘤学终于成熟了，EJSO继续在传播与该外科相关的信息和知识方面发挥着重要作用。每年出版八次，向外科肿瘤学家提供最新的文章和最新的评论。此外，论文还发表在化疗、放疗、流行病学和癌症病理学方面。发表的文章也反映了实验室和临床医生之间交流的重要性。特点包括：临床试验部分临床辩论部分早期“快速通道”出版物定期回顾教育部分研究领域包括：流行病学和肿瘤诊断预防方面，包括影像学治疗的各个方面，包括放射治疗和化疗新设备在外科和临床中的应用。肿瘤学评估肿瘤治疗病例报告结果的方法，推进了与肿瘤学EJSO相关的临床和病理学知识计算，其摘要/索引方法为：索引Medicus；EMBASE；ASCA；科学引文索引。

申请加急绿色通道，投稿周期比同行快2-3个月现在咨询

EJSO 期刊中科院评价数据

影响因子趋势图

无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询

EJSO 期刊CiteScore评价数据

CiteScore排名

序号

类别

排名

百分位

CiteScore趋势图

Scopus涵盖范围

无法辨别期刊质量？专业编辑老师一对一讲解，现在咨询现在咨询

EJSO 期刊常见问题

权益保障

刊物信息可查

推荐刊物均可到国家新闻出
版总署网站查询正刊
严格保密协协议

可签署保密协议，不透露任
何用户信息可跟踪进程，全程
协议
售后服务保障

1对1服务，7x24小时在线
企业信誉保障

16年经验沉淀，实体公司
运营

EJSO 投稿经验

(由下方点评分析获得，5人参与，28681人阅读）

偏重的研究方向：

肿瘤 (3) 基础 (1) 临床 (1) 外科 (1)
投稿录用比例：

暂无
审稿速度：

平均9.6666666666667个月的审稿周期(非官方数据)

大类(学科)	小类(学科)	学科排名
医学	ONCOLOGY(肿瘤学) 3区 SURGERY(外科学) 2区	87/223 24/200

年度总发文量	年度论文发表量	年度综述发表量
278	220	58

Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study.

EJSO

EJSO-EUR J SURG ONC

EJSO 期刊简介

英文简介：

中文简介：（来自Google、百度翻译）

EJSO 期刊中科院评价数据

最新中科院分区

最新公布的期刊年发文量

影响因子趋势图

EJSO 期刊CiteScore评价数据

最新CiteScore值

CiteScore排名

CiteScore趋势图

Scopus涵盖范围

EJSO 期刊常见问题

热门常见问题

权益保障

刊物信息可查

严格保密协协议

售后服务保障

企业信誉保障

EJSO 投稿经验

最新评论(不代表本站观点)

360期刊网

Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study.

EJSO

EJSO-EUR J SURG ONC

EJSO 期刊简介

英文简介：

中文简介：（来自Google、百度翻译）

EJSO 期刊中科院评价数据

最新中科院分区

最新公布的期刊年发文量

影响因子趋势图

EJSO 期刊CiteScore评价数据

最新CiteScore值

CiteScore排名

CiteScore趋势图

Scopus涵盖范围

EJSO 期刊常见问题

热门常见问题

权益保障

刊物信息可查

严格保密协协议

售后服务保障

企业信誉保障

EJSO 投稿经验

最新评论(不代表本站观点)

相关期刊

360期刊网